Callisto Intends to Move Guanilib into Clinical Trials in
Ulcerative Colitis
Announces Positive Data in Animal Models of Ulcerative Colitis
NEW YORK, April 05, 2007 /PRNewswire-FirstCall/ -- Callisto
Pharmaceuticals, Inc. , a developer of new drug treatments in the
fight against cancer and other major health threats, announced
today additional data confirming efficacy of G...
Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
... significantly reduced cardiotoxicity, or damage to the
heart, compared to currently available drug alternatives. Callisto also has
a proprietary drug
guanilib in preclinical development for gastro-
intestinal disorders. Callisto has exclusive worldwide licenses from
Genzyme Inc. and M.D. Anderson Cancer Cent...
Callisto Reports on Second-Quarter 2007 Milestones
...s currently suffering from these maladies." About
guanilib guanilib (also called SP-304) is a potent analog (synthetic...llisto scientists, and is proprietary to
Callisto.
guanilib has been demonstrated to be superior to uroguanyli...
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
... significantly reduced cardiotoxicity, or damage to the
heart, compared to currently available drug alternatives. Callisto also has
a proprietary drug
guanilib in preclinical development for gastro-
intestinal disorders. Callisto has exclusive worldwide licenses from
Genzyme Inc. and M.D. Anderson Cancer Cent...